1. Home
  2. VIGL vs LEE Comparison

VIGL vs LEE Comparison

Compare VIGL & LEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • LEE
  • Stock Information
  • Founded
  • VIGL 2020
  • LEE 1890
  • Country
  • VIGL United States
  • LEE United States
  • Employees
  • VIGL N/A
  • LEE N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • LEE Newspapers/Magazines
  • Sector
  • VIGL Health Care
  • LEE Consumer Discretionary
  • Exchange
  • VIGL Nasdaq
  • LEE Nasdaq
  • Market Cap
  • VIGL 89.3M
  • LEE 90.6M
  • IPO Year
  • VIGL 2022
  • LEE N/A
  • Fundamental
  • Price
  • VIGL $2.76
  • LEE $11.46
  • Analyst Decision
  • VIGL Strong Buy
  • LEE
  • Analyst Count
  • VIGL 5
  • LEE 0
  • Target Price
  • VIGL $21.00
  • LEE N/A
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • LEE 23.4K
  • Earning Date
  • VIGL 03-25-2025
  • LEE 02-06-2025
  • Dividend Yield
  • VIGL N/A
  • LEE N/A
  • EPS Growth
  • VIGL N/A
  • LEE N/A
  • EPS
  • VIGL N/A
  • LEE N/A
  • Revenue
  • VIGL N/A
  • LEE $600,264,000.00
  • Revenue This Year
  • VIGL N/A
  • LEE N/A
  • Revenue Next Year
  • VIGL N/A
  • LEE N/A
  • P/E Ratio
  • VIGL N/A
  • LEE N/A
  • Revenue Growth
  • VIGL N/A
  • LEE N/A
  • 52 Week Low
  • VIGL $1.49
  • LEE $7.57
  • 52 Week High
  • VIGL $6.06
  • LEE $19.63
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 70.15
  • LEE 32.32
  • Support Level
  • VIGL $2.54
  • LEE $11.40
  • Resistance Level
  • VIGL $2.88
  • LEE $13.69
  • Average True Range (ATR)
  • VIGL 0.22
  • LEE 0.80
  • MACD
  • VIGL 0.03
  • LEE -0.10
  • Stochastic Oscillator
  • VIGL 85.19
  • LEE 6.58

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

Share on Social Networks: